biosim ai logoBiosim AI, founded by a professor at the University of Maryland in College Park, has closed on $12.25 million in its bid to commercialize technology to “enable and accelerate drug discovery at quantum accuracy.” So far, the company has raised $13 million, with investors including Armenia’s SmartGate VC, according to Crunchbase.

Armenian-born Garegin Papoian, Monroe Martin Professor at UMD’s Chemistry & Biochemistry and Institute for Physical Science and Technology, founded Biosim AI in 2020, raising a small pre-seed investment from his home country firm, SmartGate VC.

Still in Stealth

Years later, the company remains in stealth mode, with a sparsely-filled single-page website, with little information. “It will take hundreds of years to cure human diseases. We will accelerate this timeline,’ the company says on its home page. “Stay tuned.”

Papoian received a PhD in Quantum Chemistry from Cornell University in 1999, after completing his undergraduate studies at the Russian Academy of Sciences in Moscow. According to an Amazon site publishing information on its scientific research, Papoian has focused on “computational modeling of biological molecules like proteins and DNA,” and “protein structure prediction,” which can be used to design drugs.

“When you design a drug, you need to know what the target looks like,” Papoian said in an interview. “If you know that the target protein has a certain pocket, for example, you can develop a molecule that will fit nicely into that pocket.”

Click here to read more via CityBiz+